mannitol has been researched along with ciprofloxacin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghuloum, AM; Jain, AN; Sage, CR | 1 |
| Ertl, P; Rohde, B; Selzer, P | 1 |
| Artursson, P; Luthman, K; Norinder, U; Stenberg, P | 1 |
| Caron, G; Ermondi, G | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cavet, ME; Simmons, NL; West, M | 1 |
| Ghosn, MG; Larin, KV; Tuchin, VV | 1 |
| Adi, H; Agus, H; Chan, HK; Traini, D; Young, PM | 1 |
| Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y | 1 |
| Anderson, SD; Daviskas, E; Ong, HX; Salama, R; Traini, D; Young, PM | 1 |
| Chan, HK; Crapper, J; Philips, G; Sharma, K; Traini, D; Young, PM | 1 |
| Farkas, DR; Hindle, M; Longest, PW | 1 |
| Chew, JW; Hadinoto, K; Teo, J; Yu, H | 1 |
| Cipolla, D; Lauretani, G; Lee, WH; Loo, CY; Ong, HX; Scalia, S; Traini, D; Young, P | 1 |
| Bhujbal, S; Mangal, S; Park, H; Shetty, N; Zemlyanov, D; Zhou, QT | 1 |
| Abisheganaden, JA; Chandrasekaran, R; Chotirmall, SH; Hadinoto, K; Koh, MS; Lim, AYH; Low, TB; Roizman, D; Tan, GL; Teo, J; Tran, TT; Vidaillac, C; Yong, VFL; Yu, H | 1 |
| Farhangi, M; Kobarfard, F; Mahboubi, A; Mortazavi, SA; Vatanara, A | 1 |
| Huang, Z; Jiang, J; Li, G; Lin, L; Liu, C; Lv, L; Quan, G; Wu, C; Wu, Q; Yu, X | 1 |
1 review(s) available for mannitol and ciprofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
21 other study(ies) available for mannitol and ciprofloxacin
| Article | Year |
|---|---|
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
Topics: Drug Design; Intestinal Absorption; Models, Molecular; Pharmaceutical Preparations; Structure-Activity Relationship | 1999 |
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Topics: Biological Availability; Biological Transport; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Reproducibility of Results | 2000 |
Experimental and computational screening models for the prediction of intestinal drug absorption.
Topics: Biological Transport; Carbon Radioisotopes; Cell Line; Cell Membrane; Cell Membrane Permeability; Ciprofloxacin; Computational Biology; Drug Design; Foscarnet; Humans; Hydrogen Bonding; Intestinal Absorption; Intestinal Mucosa; Lactulose; Mannitol; Models, Biological; Raffinose; Surface Properties; Tritium; Verapamil | 2001 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.
Topics: Anti-Infective Agents; Biological Transport; Caco-2 Cells; Cell Membrane Permeability; Ciprofloxacin; Digoxin; Epithelial Cells; Humans; Lung; Mannitol; Vincristine | 1997 |
Nondestructive quantification of analyte diffusion in cornea and sclera using optical coherence tomography.
Topics: Animals; Biological Transport; Ciprofloxacin; Cornea; Dexamethasone; Mannitol; Metronidazole; Permeability; Pilot Projects; Rabbits; Sclera; Tissue Distribution; Tomography, Optical Coherence | 2007 |
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Drug Combinations; Humans; Mannitol; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Powders; Pseudomonas aeruginosa; Pulmonary Disease, Chronic Obstructive; Staphylococcus aureus; Streptococcus pyogenes | 2010 |
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Humans; Mannitol; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections; Sodium Chloride | 2011 |
The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia.
Topics: Biological Transport; Cell Line; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Mannitol; Particle Size; Respiratory Mucosa | 2013 |
Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Topics: Aerosols; Anti-Bacterial Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Ciprofloxacin; Crystallography, X-Ray; Drug Combinations; Drug Delivery Systems; Dry Powder Inhalers; Equipment Design; Expectorants; Humans; Mannitol; Microscopy, Electron, Scanning; Particle Size; Powder Diffraction; Powders; Respiratory Tract Infections | 2014 |
Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.
Topics: Aerosols; Anti-Bacterial Agents; Ciprofloxacin; Dry Powder Inhalers; Equipment Design; Excipients; Mannitol; Particle Size; Powders; Pressure | 2015 |
Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Topics: Aerosols; Anti-Bacterial Agents; Bronchiectasis; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Compounding; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Freeze Drying; Leucine; Mannitol; Nanoparticles; Particle Size; Pseudomonas aeruginosa | 2016 |
Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chronic Disease; Ciprofloxacin; Drug Combinations; Drug Resistance, Bacterial; Humans; Mannitol; Nebulizers and Vaporizers; Permeability; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2018 |
Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Ciprofloxacin; Desiccation; Disaccharides; Drug Compounding; Drug Stability; Excipients; Humidity; Leucine; Mannitol; Particle Size; Powders | 2018 |
A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Case-Control Studies; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Humans; Lactose; Lung; Mannitol; Mucus; Permeability; Pseudomonas aeruginosa | 2018 |
Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Desiccation; Drug Liberation; Dry Powder Inhalers; Excipients; Humans; Klebsiella pneumoniae; Mannitol; Micelles; Nanoparticles; Particle Size; Phenylalanine; Polymers; Powders; Pseudomonas aeruginosa; Streptococcus pneumoniae | 2019 |
Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Dry Powder Inhalers; Fibroins; Humans; Mannitol; Particle Size | 2019 |